Tag: clinical research misconduct cases

  • Research Misconduct Case Studies: The 3-Stage Investigation Pattern

    Research misconduct case studies, read across institutions and years rather than one scandal at a time, show a repeatable pattern: a three-stage process (assessment, inquiry/investigation, appeal), a civil “preponderance of the evidence” standard rather than criminal proof, and appeal routes that vary sharply between the United States, the United Kingdom, and the European Union. Benchmarking against this pattern — not against any single named case — is what lets a research integrity officer (RIO) judge whether their own procedure is fit for purpose.

    A research misconduct case is formally defined, under the United States’ federal regulation for Public Health Service (PHS)-funded research, as fabrication, falsification, or plagiarism (FFP), committed intentionally, knowingly, or recklessly. This article sets aside individual identities and instead compares the procedural architecture that concluded cases reveal, so integrity officers and research administration teams can stress-test their own workflow against a documented, cross-jurisdictional standard. Related terminology is catalogued in the CASRAI research administration dictionary.

    What the three-stage investigation process reveals

    Every concluded United States case that falls under PHS funding follows the same skeleton set out in the federal research misconduct regulation, 42 CFR Part 93. Stripped of case-specific detail, the pattern is procedural, not narrative, and it repeats regardless of discipline or seniority of the respondent.

    1. Assessment. The institution’s Research Integrity Officer screens the allegation to confirm it falls within the FFP definition and that the accused conducted the work under covered funding.
    2. Inquiry. A preliminary, fact-finding review determines whether a full investigation is warranted. Under 42 CFR §93.307, institutions are expected to complete the inquiry within 60 days of initiation, extendable only with a documented justification in the record.
    3. Investigation. A committee examines sequestered research records, notebooks, and raw data in full. Per 42 CFR §93.311, the Office of Research Integrity (ORI) expects institutions to complete this stage within 120 days, with the respondent given an opportunity to comment on the draft report before it is finalised.

    The consistency of this three-stage architecture across decades of closed ORI case summaries is itself the diagnostic tool: cases that stall well past 60 or 120 days, or skip straight from allegation to sanction without a documented inquiry, are the ones most likely to be overturned on appeal.

    What standard of proof applies in research misconduct cases

    Research misconduct findings are civil, not criminal, determinations. Under 42 CFR §93.106(b), a finding requires proof by a preponderance of the evidence — that the alleged conduct is more likely than not to have occurred — rather than the “beyond reasonable doubt” threshold used in criminal law.

    Three elements must all be satisfied for a finding to stand:

    • The conduct represents a significant departure from accepted practices in the relevant research community.
    • The act was committed intentionally, knowingly, or recklessly — honest error and legitimate differences of scientific interpretation are explicitly excluded.
    • The allegation is proven by a preponderance of the evidence assembled during the inquiry and investigation stages.

    This is a materially lower bar than criminal fraud statutes, which is precisely why institutions can act on data-integrity concerns years before — or entirely without — any parallel criminal or civil litigation. In the United Kingdom, no single statutory standard applies; the Concordat to Support Research Integrity, published by Universities UK, commits signatory institutions to “robust and fair” procedures but leaves the specific evidentiary threshold to each institution’s own disciplinary regulations, typically the civil “balance of probabilities” test familiar from UK employment law.

    What appeal routes exist after a misconduct finding

    Appeal architecture is where the US and UK systems diverge most sharply, and it is the least-benchmarked part of most institutional policies.

    In the US federal system, a respondent facing a proposed debarment or suspension of federal funding eligibility can request a hearing before a Departmental Appeals Board (DAB) Administrative Law Judge, under the appeal provisions of 42 CFR Part 93, Subpart D. The ALJ hearing allows both ORI and the respondent to present evidence, and courts have previously found in favour of respondents where an agency denied a hearing without adequate justification — underscoring that procedural due process, not just the underlying evidence, is independently reviewable.

    In the UK, there is no equivalent national appellate body. Appeals run through each institution’s own internal grievance or disciplinary panel, sitting outside the original investigating committee. UKRIO offers independent advisory input on request but has no statutory power to overturn or reopen a case. Where a funder, rather than an employer, makes the finding — for instance under a UKRI grant condition — the appeal route sits with the funder’s own review process, separate from the host institution’s route.

    How timelines and procedures compare across jurisdictions

    The table below compares the procedural pattern documented in concluded cases across the three frameworks a UK-based or internationally funded institution is most likely to encounter.

    Framework Governing document Recommended timeline Standard of proof Appeal route
    US federal (PHS-funded) 42 CFR Part 93 (ORI) Inquiry: 60 days; Investigation: 120 days Preponderance of the evidence HHS Departmental Appeals Board ALJ hearing
    UK institutional Concordat to Support Research Integrity (Universities UK) Set by each institution’s own policy; no fixed statutory deadline Balance of probabilities (institution-defined) Internal grievance/appeal panel; UKRIO advisory only
    EU / Horizon Europe European Code of Conduct for Research Integrity (ALLEA, revised 2023) Left to national/institutional implementation Not standardised; varies by member state National research integrity body or institutional route, depending on country

    The gap this table exposes is one most institutional policies fail to acknowledge in writing: US regulation fixes an evidentiary standard and a timeline in federal law, while UK and EU frameworks fix principles but delegate both to the institution or member state. For an internationally funded research group, the applicable standard of proof can therefore change depending on which funder paid for the disputed work — a fact case files consistently reveal once cross-border co-authorship is involved.

    Frequently asked questions

    What counts as research misconduct in a case study?

    Under US federal regulation and the frameworks it has influenced internationally, research misconduct is defined as fabrication, falsification, or plagiarism (FFP) committed intentionally, knowingly, or recklessly. It excludes honest error, authorship disputes, and good-faith differences in data interpretation or experimental design.

    How long does a research misconduct investigation take?

    Under 42 CFR Part 93, US institutions are expected to complete an inquiry within 60 days and a full investigation within 120 days of initiation. UK and EU frameworks set no equivalent statutory deadline, so timelines vary considerably by institution and case complexity.

    What standard of proof is used to find research misconduct?

    The applicable US standard is a preponderance of the evidence — more likely than not — rather than criminal-level proof. UK institutions typically apply the analogous civil balance of probabilities test under their own disciplinary regulations, since no single UK statutory standard exists.

    Can a researcher appeal a research misconduct finding?

    Yes. US respondents facing federal debarment can request a hearing before an HHS Departmental Appeals Board Administrative Law Judge. UK researchers appeal through their institution’s internal grievance or disciplinary panel, since no national appellate body for misconduct findings currently exists.

    What this means for research integrity officers

    Reading concluded cases for procedural pattern, rather than for scandal detail, produces a practical benchmarking checklist that any RIO can apply to their own institution’s policy:

    • Does the policy document a fixed inquiry and investigation timeline, and is it consistently met in closed cases?
    • Is the standard of proof — preponderance of the evidence or balance of probabilities — stated explicitly, rather than implied?
    • Is the appeal route independent of the original investigating committee, with named escalation steps?
    • Where research is co-funded across US, UK, or EU sources, does the policy specify which framework’s standard applies?
    • Are sequestration procedures for research records triggered automatically at the inquiry stage, not the investigation stage?

    Institutions that can answer all five points in writing sit closer to the documented federal pattern than those relying on ad hoc, case-by-case discretion — and case files show procedural gaps, not evidentiary weakness, are the most common ground on which findings are successfully challenged. As research increasingly crosses funder and jurisdictional boundaries, benchmarking process design against this comparative pattern, rather than against any single high-profile case, is becoming a core, auditable component of institutional research governance.

  • Research Misconduct GCP vs ORI: Key Differences

    Research misconduct GCP rules cover more ground than the academic misconduct standard researchers may already know. Under FDA bioresearch-monitoring (BIMO) authority and Good Clinical Practice, misconduct in a clinical trial can include protocol violations, unprotected human subjects and data-integrity failures — not only fabrication, falsification or plagiarism. This creates a parallel compliance track that runs alongside, and sometimes collides with, the Office of Research Integrity’s (ORI) Public Health Service (PHS) misconduct policy.

    Research misconduct, under 42 CFR Part 93, is defined by ORI as “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results” — committed intentionally, knowingly, or recklessly, and representing a significant departure from accepted practice. GCP misconduct, by contrast, is judged against compliance with the trial protocol, informed-consent rules and data-integrity requirements set out in FDA regulations, and does not hinge on the same intent test.

    What Counts as Research Misconduct Under FDA and GCP Rules?

    FDA’s Bioresearch Monitoring programme inspects clinical investigators, sponsors, monitors and institutional review boards for compliance with clinical trial regulations, principally 21 CFR Parts 50, 56 and 312 and the internationally harmonised ICH E6(R2) Good Clinical Practice guideline. Misconduct in this context extends well beyond fabrication, falsification and plagiarism (FFP).

    It can include failing to protect human subjects, proceeding without valid informed consent, deviating repeatedly from the approved protocol, or under-reporting adverse events. FDA inspectors have described a lower practical bar for sanction than the PHS intent standard: repeated or negligent noncompliance with GCP can itself justify action, even without proof of deliberate deception.

    How Does ORI/PHS Academic Misconduct Policy Differ?

    ORI oversees institutions receiving PHS funding — chiefly NIH grants — under the narrower FFP definition. A finding requires evidence of intent (“intentionally, knowingly, or recklessly”) and a significant departure from accepted research practice. Honest error and genuine differences of scientific opinion are explicitly excluded.

    The table below sets out the core distinctions between the two frameworks.

    Dimension ORI/PHS academic policy FDA GCP/BIMO framework
    Core definition Fabrication, falsification, plagiarism (FFP) FFP plus GCP deviations: consent failures, protocol breaches, data-integrity gaps
    Governing rule 42 CFR Part 93 21 CFR Parts 50, 56, 312; ICH E6(R2)
    Intent threshold Intentional, knowing or reckless; “significant departure” Can extend to negligent or repeated noncompliance
    Jurisdiction PHS-funded research only Any trial data submitted to FDA in a marketing application, funded or not
    Investigator Institutional integrity officer, ORI oversight FDA Office of Scientific Investigations / BIMO inspectors
    Typical sanction Federal funding debarment, supervision, record correction Clinical investigator disqualification (21 CFR 312.70), data rejection, debarment

    The practical consequence: a fully compliant academic institution can still have a GCP problem, and a well-run industry trial with no PHS funding at all is entirely outside ORI’s remit but squarely inside FDA’s.

    What Triggers an FDA Bioresearch-Monitoring Investigation?

    BIMO inspections are risk-based and routine as well as complaint-driven. FDA selects clinical investigator sites for inspection using data anomalies, unusually favourable results, high enrolment rates, complaints, or as a standard check ahead of marketing-application review.

    • Falsified or fabricated case-report-form data submitted in an IND or NDA;
    • Repeated protocol deviations affecting subject safety or data validity;
    • Informed-consent documentation failures under 21 CFR Part 50;
    • Institutional review board oversight lapses under 21 CFR Part 56;
    • Undisclosed financial conflicts of interest affecting trial conduct.

    Confirmed findings can lead to disqualification of a clinical investigator under 21 CFR 312.70, rejection of the affected data from a submission, referral for criminal prosecution, or debarment under the Federal Food, Drug, and Cosmetic Act’s Application Integrity Policy.

    What Happens When a Trial Falls Under Both Frameworks?

    Many clinical trials are simultaneously NIH-funded (triggering PHS/ORI jurisdiction) and submitted to FDA in support of an IND or marketing application (triggering GCP/BIMO jurisdiction). In that scenario, a single allegation can spawn two parallel investigations, run by different bodies, applying different definitions, evidentiary thresholds and remedies.

    ORI’s process centres on correcting the scientific record and imposing funding-related sanctions on the individual researcher. FDA’s process centres on protecting trial subjects and the integrity of data submitted for regulatory approval, and can act against a sponsor, monitor or institution as well as an investigator. Research administrators managing multi-funded trials need policies that map obligations under both tracks, since satisfying one does not discharge the other.

    For institutions, the practical implication is a dual-reporting duty: allegations touching FDA-regulated data may need parallel notification to the institution’s research integrity officer and, where applicable, to the FDA sponsor or IND holder — a distinction general research-misconduct training rarely covers.

    Frequently Asked Questions

    What are the three types of research misconduct?

    Under ORI/PHS policy, the three recognised types are fabrication (making up data), falsification (manipulating materials or omitting results) and plagiarism (using others’ work without credit) — collectively known as FFP. FDA/GCP rules recognise these plus separate categories tied to human-subject protection and protocol compliance.

    What counts as research misconduct?

    Research misconduct is conduct that deliberately or recklessly falls short of accepted research standards, spanning proposal, conduct and reporting. Under GCP, it also covers protocol deviations, invalid consent and unreported adverse events — behaviours the narrower academic FFP definition does not automatically capture.

    What are some examples of research misconduct?

    Examples include fabricating patient outcomes, falsifying case-report-form entries, plagiarising a manuscript, enrolling subjects without valid informed consent, and concealing a serious adverse event from a sponsor or IRB. The last three are GCP-specific failures with no direct ORI/PHS equivalent.

    What are the 5 unethical practices in research?

    Commonly cited categories are falsification of data, failure to credit others, plagiarism, undisclosed conflicts of interest, and biased design or interpretation. In FDA-regulated trials, a sixth practical category applies: noncompliance with GCP itself, regardless of intent.

    As FDA-regulated trials grow more complex and more federally co-funded research crosses into the BIMO’s remit, institutions running clinical research increasingly need compliance frameworks built to satisfy both standards concurrently, rather than treating GCP obligations as an addendum to existing academic misconduct policy. Building that dual-track literacy into institutional training is the clearest way to close the gap this comparison exposes.

    For related institutional context, see CASRAI’s overview of research administration compliance frameworks and the research integrity dictionary for definitions of adjacent terms.